Immunocore Holdings plc Weighted Average Fair Value At Measurement Date Share Options Granted
Immunocore Holdings plc (IMCR) had Weighted Average Fair Value At Measurement Date Share Options Granted of $16.93 thousand as of 2022-12-31, per its 20-F filed 2023-03-01.
Discontinued › Notes
ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted · last filed 2023-03-01
- 2020-12-31: Weighted Average Fair Value At Measurement Date Share Options Granted 33.40K GBP.
- 2019-12-31: Weighted Average Fair Value At Measurement Date Share Options Granted 11.95K GBP.
- 2018-12-31: Weighted Average Fair Value At Measurement Date Share Options Granted 0.00 GBP.
GBP
| Period end | Weighted Average Fair Value At Measurement Date Share Options Granted |
|---|---|
| 2020-12-31 | 33.40K GBP 20-F · filed 2021-03-25 |
| 2019-12-31 | 11.95K GBP 20-F · filed 2021-03-25 |
| 2018-12-31 | 0.00 GBP 20-F · filed 2021-03-25 |
USD
| Period end | Weighted Average Fair Value At Measurement Date Share Options Granted |
|---|---|
| 2022-12-31 | $16.93K 20-F · filed 2023-03-01 |
| 2021-12-31 | $16.48K 20-F · filed 2023-03-01 |
| 2020-12-31 | $9.11K 20-F · filed 2023-03-01 |
| 2019-12-31 | $3.26K 20-F · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |